MyMD Pharmaceuticals Announces U.S. DEA Determines Supera-CBD is not a Controlled Substance or Listed Chemical
MYMDDelisted Stock | USD 1.82 0.02 1.09% |
About 61% of MyMD Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in MyMD Pharmaceuticals suggests that many traders are alarmed regarding MyMD Pharmaceuticals' prospects. The current market sentiment, together with MyMD Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use MyMD Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
MyMD |
MyMD Pharmaceuticals Announces U.S. DEA Determines Supera-CBD is not a Controlled Substance or Listed Chemical
Read at investing.com
MyMD Pharmaceuticals Fundamental Analysis
We analyze MyMD Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MyMD Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MyMD Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
MyMD Pharmaceuticals is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
MyMD Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MyMD Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of MyMD Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MyMD Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
MyMD Pharmaceuticals Related Equities
SRZN | Surrozen | 20.75 | ||||
REVB | Revelation Biosciences | 16.67 | ||||
NVCT | Nuvectis Pharma | 9.25 | ||||
LYEL | Lyell Immunopharma | 6.51 | ||||
LYRA | Lyra Therapeutics | 5.88 | ||||
LRMR | Larimar Therapeutics | 5.82 | ||||
RXRX | Recursion Pharmaceuticals | 5.80 | ||||
NBY | NovaBay Pharmaceuticals | 4.96 | ||||
KZR | Kezar Life | 4.27 | ||||
UBX | Unity Biotechnology | 4.00 | ||||
GOVX | GeoVax Labs | 3.98 | ||||
REPL | Replimune | 2.32 | ||||
DSGN | Design Therapeutics | 2.20 | ||||
ORIC | Oric Pharmaceuticals | 1.83 | ||||
PASG | Passage Bio | 1.52 | ||||
GOSS | Gossamer Bio | 1.19 | ||||
LGND | Ligand Pharmaceuticals | 0.77 | ||||
KROS | Keros Therapeutics | 0.60 | ||||
BOLT | Bolt Biotherapeutics | 0.06 | ||||
AVIR | Atea Pharmaceuticals | 0.00 | ||||
XBIO | Xenetic Biosciences | 2.65 | ||||
KRON | Kronos Bio | 3.16 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in MyMD Stock
If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |